HK1056182A1 - Reshaped monoclonal antibodies against an immunoglobulin isotype - Google Patents

Reshaped monoclonal antibodies against an immunoglobulin isotype

Info

Publication number
HK1056182A1
HK1056182A1 HK03108492A HK03108492A HK1056182A1 HK 1056182 A1 HK1056182 A1 HK 1056182A1 HK 03108492 A HK03108492 A HK 03108492A HK 03108492 A HK03108492 A HK 03108492A HK 1056182 A1 HK1056182 A1 HK 1056182A1
Authority
HK
Hong Kong
Prior art keywords
monoclonal antibodies
antibodies against
immunoglobulin isotype
reshaped
reshaped monoclonal
Prior art date
Application number
HK03108492A
Other languages
English (en)
Inventor
Norman Hardman
Frand Kolbinger
Jose Saldanha
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929220228A external-priority patent/GB9220228D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HK1056182A1 publication Critical patent/HK1056182A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6873—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an immunoglobulin; the antibody being an anti-idiotypic antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
HK03108492A 1992-09-24 2003-11-21 Reshaped monoclonal antibodies against an immunoglobulin isotype HK1056182A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929220228A GB9220228D0 (en) 1992-09-24 1992-09-24 Reshaped monoclonal antibodies against an immunologlobulin isotype
US95280292A 1992-09-25 1992-09-25

Publications (1)

Publication Number Publication Date
HK1056182A1 true HK1056182A1 (en) 2004-02-06

Family

ID=26301683

Family Applications (1)

Application Number Title Priority Date Filing Date
HK03108492A HK1056182A1 (en) 1992-09-24 2003-11-21 Reshaped monoclonal antibodies against an immunoglobulin isotype

Country Status (18)

Country Link
EP (2) EP1452542A3 (da)
JP (2) JP3636737B2 (da)
KR (1) KR100298608B1 (da)
CN (2) CN1078250C (da)
AT (1) ATE264388T1 (da)
AU (1) AU675449B2 (da)
CA (1) CA2106719C (da)
CY (1) CY2583B2 (da)
DE (1) DE69333484T2 (da)
DK (1) DK0589840T3 (da)
ES (1) ES2219640T3 (da)
FI (2) FI114550B (da)
HK (1) HK1056182A1 (da)
IL (2) IL173988A0 (da)
MX (1) MX9305920A (da)
NO (1) NO318210B1 (da)
NZ (1) NZ248743A (da)
PT (1) PT589840E (da)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA966075B (en) * 1995-07-27 1998-01-19 Genentech Inc Protein formulation.
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
WO1997010004A1 (en) * 1995-09-13 1997-03-20 Genentech, Inc. Methods for treatment of interstitial cystitis
US6127524A (en) * 1996-10-18 2000-10-03 Dade Behring Inc. Binding molecules and computer-based methods of increasing the binding affinity thereof
CN1289253A (zh) * 1998-01-29 2001-03-28 泰诺士公司 以lgE拮抗剂治疗特应性皮炎
EP1558647B1 (en) * 2002-11-08 2015-06-10 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
EP3299393A1 (en) 2002-11-08 2018-03-28 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
US20060034845A1 (en) 2002-11-08 2006-02-16 Karen Silence Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
US9320792B2 (en) 2002-11-08 2016-04-26 Ablynx N.V. Pulmonary administration of immunoglobulin single variable domains and constructs thereof
WO2004070010A2 (en) * 2003-02-01 2004-08-19 Tanox, Inc. A method for generating high affinity antibodies
CA2552999A1 (en) * 2004-02-02 2005-08-18 Tanox, Inc. Identification of novel ige epitopes
EP4104821A1 (en) 2008-10-29 2022-12-21 Ablynx N.V. Formulations of single domain antigen binding molecules
US10118962B2 (en) 2008-10-29 2018-11-06 Ablynx N.V. Methods for purification of single domain antigen binding molecules

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0617127A1 (en) * 1987-12-31 1994-09-28 Tanox Biosystems, Inc. Antigenic epitopes on B cell-bound IgE Immunoglobulins
US5104604A (en) * 1989-10-05 1992-04-14 Dexter Electronic Materials Div. Of Dexter Corp. Flame retardant epoxy molding compound, method and encapsulated device method of encapsulating a semiconductor device with a flame retardant epoxy molding compound
JP2988635B2 (ja) * 1990-09-18 1999-12-13 塩野義製薬株式会社 ヒトＩｇＥに対するモノクローナル抗体
WO1992017207A1 (en) * 1991-03-26 1992-10-15 Tanox Biosystems, Inc. MONOCLONAL ANTIBODIES WHICH BIND TO SECRETED AND MEMBRANE-BOUND IgE, BUT NOT TO IgE ON BASOPHILS
EP0602126B1 (en) * 1991-08-14 2003-03-05 Genentech, Inc. Immunoglobulin variants for specific fc epsilon receptors

Also Published As

Publication number Publication date
KR100298608B1 (ko) 2001-11-22
DK0589840T3 (da) 2004-07-26
FI114550B (fi) 2004-11-15
FI115838B (fi) 2005-07-29
IL107049A (en) 2006-07-05
IL107049A0 (en) 1993-12-28
MX9305920A (es) 1994-05-31
CN1078250C (zh) 2002-01-23
NO933394L (no) 1994-03-25
CA2106719A1 (en) 1994-03-25
NO933394D0 (no) 1993-09-23
ES2219640T3 (es) 2004-12-01
EP0589840B1 (en) 2004-04-14
CY2583B2 (en) 2009-11-04
DE69333484T2 (de) 2005-03-24
JP2004357712A (ja) 2004-12-24
JP3718214B2 (ja) 2005-11-24
EP0589840A1 (en) 1994-03-30
KR940006602A (ko) 1994-04-25
DE69333484D1 (de) 2004-05-19
EP1452542A3 (en) 2007-05-02
CN1254487C (zh) 2006-05-03
FI934145A0 (fi) 1993-09-22
CA2106719C (en) 2006-03-28
JP3636737B2 (ja) 2005-04-06
ATE264388T1 (de) 2004-04-15
AU4748893A (en) 1994-03-31
FI20040696A (fi) 2004-05-19
JPH06225788A (ja) 1994-08-16
PT589840E (pt) 2004-08-31
CN1088986A (zh) 1994-07-06
IL173988A0 (en) 2006-07-05
FI934145A (fi) 1994-03-25
AU675449B2 (en) 1997-02-06
EP1452542A2 (en) 2004-09-01
NO318210B1 (no) 2005-02-21
CN1428352A (zh) 2003-07-09
NZ248743A (en) 1995-04-27

Similar Documents

Publication Publication Date Title
CY2583B2 (en) Reshaped monoclonal antibodies against an immunoglobulin isotype
TR199900722T2 (xx) Yeniden kurulmu� insan anti-HM1.24 antikoru.
FR12C0004I1 (da)
DK0758904T3 (da) Fremgangsmåder og sammensætninger til behandling af glomerulonephritis
HUT74272A (en) Immunoglobulin g concentrate for therapeutical use and method for producing same
EP0675734A4 (en) ALLERGY SPECIFIC, MONOCLONAL IgA ANTIBODIES AND SIMILAR PRODUCTS FOR ALLERGY TREATMENT.
ATE166230T1 (de) Verwendung von anti-icam antikörpern zur herstellung eines präparats für die behandlung von endotoxinschock
ATE151078T1 (de) Verfahren und zwischenprodukte synthetischer antikörperderivate
EP0396505A3 (en) Monoclonal antibodies specific for an immunoglobulin isotype
ES2100892T3 (es) Tratamiento de enfermedades autoinmunitarias.
MX9301858A (es) Anticuerpos monoclonales neutralizantes de hiv-humano recombinante para prevencion y tratamiento de infeccion hiv.
RU93035807A (ru) Способ лечения юношеского эпифизиолиса
GB9220228D0 (en) Reshaped monoclonal antibodies against an immunologlobulin isotype

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20100924